SCHEMBL4931844

SCHEMBL4931844

CNC(=O)C1CNCCN1c1cccc(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 7/20 0.47
HTR2A P28223 6/20 0.47
HTR2B P41595 6/20 0.47
HTR3E A5X5Y0 1/20 0.47
HTR3B O95264 1/20 0.47
TP53 P04637 1/20 0.47
CYP1A2 P05177 1/20 0.47
ADRB1 P08588 1/20 0.47
CYP3A4 P08684 1/20 0.47
HTR1A P08908 1/20 0.47
CYP2D6 P10635 1/20 0.47
THRB P10828 1/20 0.47
CYP2C9 P11712 1/20 0.47
SLC6A4 P31645 1/20 0.47
CYP2C19 P33261 1/20 0.47
HTR7 P34969 1/20 0.47
HTT P42858 1/20 0.47
HTR3A P46098 1/20 0.47
HTR6 P50406 1/20 0.47
HTR3D Q70Z44 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27523649 0.85 HTR2A (0.53) HTR2CHTR2AHTR2BHTR3EHTR3B
SCHEMBL4932313 0.83 ALDH1A1 (0.43) HTR2CHTR2AHTR2BHTR3EHTR3B
SCHEMBL4930625 0.82 HTR2A (0.44) HTR2CHTR2AHTR2BHTR3EHTR3B
SCHEMBL11139865 0.81 HTR2C (0.48) HTR2CHTR2AHTR2BHTR3EHTR3B
SCHEMBL5922625 0.80 ALDH1A1 (0.46) HTR2CHTR2AHTR2BHTR3EHTR3B
SCHEMBL23777584 0.77 HTR2C (0.55) HTR2CHTR2AHTR2BHTR3EHTR3B
SCHEMBL5630950 0.77 HTR2C (0.55) HTR2CHTR2AHTR2BHTR3EHTR3B
SCHEMBL17884647 0.77 HTR2C (0.55) HTR2CHTR2AHTR2BHTR3EHTR3B
Hydrochloric Acid SCHEMBL4934601 0.77 LMNA (0.48) TP53HTR1AHTT
SCHEMBL11166558 0.76 HTR2C (0.57) HTR2CHTR2AHTR2BHTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076338-B2 Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation EXELIXIS, INC. (US) 2011-12-13 US disclosed
US-20080076774-A1 Kinase Modulators and Methods of Use EXELIXIS, INC. (US) 2008-03-27 US disclosed
EP-1750727-A2 KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2007-02-14 EP disclosed
WO-2005117909-A2 KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076774-A1 Kinase Modulators and Methods of Use AKT3, RPS6KA3, CDK3 HTR2C 2901/4885HTR2A 3195/4885HTR2B 2608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.